HFL has a breadth of activities and capabilities spanning biomarker discovery, assay development, validation and sample analysis for preclinical and clinical development.

Biomarker Discovery

• Pioneering biomarker research for sports drug surveillance
• Mass spectrometry approaches for analysis of the proteome including HFL’s BioMSä service
• Metabo(l/n)omics

Development of Biomarker Methods

• Feasibility assessment, method establishment and development
• Experience with a variety of species and matrices
• Wide selection of analytical methodologies available
• Immunogen synthesis
• Antibody characterisation and production

Validation of Biomarker Methods

• Validation of assays developed in-house
• Verification and validation of commercial immunoassay kits
• GLP/GCP Validation in accordance with current industry recommendations

Biomarker Quantification

• Quantification of biomarkers as a measure of safety, drug efficacy or proof of mechanism
• Experience with a broad range of proteins, peptides, antibodies, small molecules, clotting factors, cytokines etc.
• Low limits of quantification  

Analytical methods & instrumentation

• ELISA, EIA, DELFIA, IRMA and RIA
• Multiplex systems under evaluation
• Olympusä , Immuliteä and Axsymä analyser systems for clinical biomarkers
• Range of detection techniques - colorimetric, radiometric, fluorescence, chemiluminescence and time resolved fluorescence
• MALDI-MS, LC-MS/MS, GC-MS/MS
• Electrophoresis and affinity chromatography
• Mitsubishi robotic system for 96/384 well plate technology incorporating Multiprobe IIä and precision pipetting using Evolution P³ systems

 

High throughput automated protein quantification using Gyrolabä platform

Using the Gyrolabä platform, HFL are able to offer:

• Enhanced performance and productivity
• Lower serum dilutions increase assay sensitivity
• Automation minimises performance failures and improves reproducibility
• Reduced sample size requirements leading to reduced reagent consumption